GSK won U.S. approval for second lung cancer drug from Nuvalent deal

GSK's neladalkib received FDA approval for treating ALK-positive non-small cell lung cancer. The drug was acquired through GSK's $10.6B Nuvalent deal. GSK's oncology sales rose 23% in Q3 to £600M. CEO Miels highlighted recent approvals, including Jideytro and Jemperli.

Original reporting
Published Nov 17, 2026, 6:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 7:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSK won U.S. approval for second lung cancer drug from Nuvalent deal — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

This is a direct regulatory milestone that converts acquired pipeline assets into U.S. commercial products, potentially improving oncology revenue trajectory and validating GSKs oncology re-entry strategy.

02

Market read

Traders can update expectations for GSKs oncology commercialization from the Nuvalent portfolio following FDA clearance.

03

What to watch

The article notes a later-phase trial is still ongoing; reimbursement, uptake speed, and confirmatory trial outcomes could drive the next valuation inflection more than the initial clearance.

Relevance 7/10Novelty 8/10Timing: FDA approval reported for U.S. clearance, with commercial implications immediately.

Background

GSK acquired Nuvalent for $10.6B, bringing in lung cancer kinase inhibitors; the FDA has now cleared neladalkib (and previously Jideytro) for specific ALK/ROS1-positive NSCLC patient populations.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

FDA cleared GSKs neladalkib for ALK-positive metastatic or locally advanced NSCLC, extending targeted-therapy options for previously treated patients.

Expected impact

Likely positive repricing as investors update the probability-weighted contribution of Nuvalent assets to GSKs oncology return.

Evidence & confidence

The article is a direct FDA approval for a drug acquired via the $10.6B Nuvalent deal, which is a concrete, tradable catalyst for GSKs pipeline commercialization.

Market effects

Reinforces demand for next-generation ALK/ROS1 kinase inhibitors and may increase competitive pressure on existing targeted-therapy franchises.

Primarily U.S. commercialization upside for GSK oncology assets, with potential follow-on updates to U.S. specialty medicine guidance.

Supports GSKs broader oncology re-entry narrative, which can influence global investor sentiment toward its pipeline execution.

Counterpoint

Accelerated approval is based on early-stage effects, so investors may discount near-term revenue durability until later-phase efficacy readouts mature.

Key entities

  • GSK

    Sponsor of neladalkib after acquiring Nuvalent; now has FDA clearance for ALK-positive metastatic or locally advanced NSCLC.

  • FDA

    Cleared neladalkib for adults with ALK-positive NSCLC after prior ALK inhibitor and/or chemotherapy exposure.

  • Nuvalent

    Acquired by GSK; deal source for neladalkib and other lung cancer assets.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

$GSKHigh

GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.